Recursion is a clinical-stage TechBio company that uses data, artificial intelligence, automated biology and chemistry to discover and develop medicines for cancer, rare diseases and other conditions.
Products & media
An investigational oral MEK1/2 inhibitor in Phase 2 development for reducing polyp burden in familial adenomatous polyposis.
An investigational MALT1 inhibitor in Phase 1 development for B-cell malignancies, designed for selective target inhibition.
An investigational PI3Kα H1047R-selective inhibitor undergoing candidate profiling for solid tumors carrying that mutation.
An investigational RBM39 degrader in Phase 1 development for selected solid tumors and lymphoma.
An investigational reversible CDK7 inhibitor in Phase 1/2 development for advanced solid tumors.
An investigational reversible, brain-penetrant LSD1 inhibitor in Phase 1 development for solid tumors and hematologic cancers.
Team
Jobs
See all jobs for Recursion here.
